Published in Future Oncol on December 01, 2009
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol (2012) 3.28
ATP-dependent chromatin remodeling in the DNA-damage response. Epigenetics Chromatin (2012) 1.12
Transcription factor-microRNA-target gene networks associated with ovarian cancer survival and recurrence. PLoS One (2013) 1.06
Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development. J Pathol (2013) 0.89
Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol (2012) 0.88
DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3β to downregulate β-catenin transcription target, osteopontin. Oncogene (2012) 0.87
p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene (2014) 0.84
MUC4 gene polymorphisms associate with endometriosis development and endometriosis-related infertility. BMC Med (2011) 0.84
Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma. Int J Gynecol Pathol (2011) 0.82
Tissue Factor-Factor VII Complex As a Key Regulator of Ovarian Cancer Phenotypes. Biomark Cancer (2015) 0.82
Knockdown of stat3 expression by RNAi inhibits in vitro growth of human ovarian cancer. Radiol Oncol (2011) 0.81
Perinatal exposure to low-dose DE-71 increases serum thyroid hormones and gonadal osteopontin gene expression. Exp Biol Med (Maywood) (2011) 0.80
RanBPM expression regulates transcriptional pathways involved in development and tumorigenesis. Am J Cancer Res (2012) 0.80
Prognostic value of rsf-1/hbxap in human solid tumors: a meta-analysis of cohort studies. Int J Clin Exp Med (2015) 0.80
Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers. J Ovarian Res (2015) 0.77
Relevance of HLA-DP/DQ and ICAM-1 SNPs among Ovarian Cancer Patients. Front Immunol (2016) 0.75
Downregulation of human epidermal growth factor receptor 2 by short hairpin RNA increases chemosensitivity of human ovarian cancer cells. Oncol Lett (2015) 0.75
Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene (1999) 13.46
Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol (2007) 10.23
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer (2007) 10.20
Ordered recruitment of transcription and chromatin remodeling factors to a cell cycle- and developmentally regulated promoter. Cell (1999) 6.83
Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet (2000) 6.61
Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res (2008) 6.47
ATP-dependent chromatin-remodeling complexes. Mol Cell Biol (2000) 5.07
Inhibition of JNK activation through NF-kappaB target genes. Nature (2001) 5.03
Ovarian cancer. Annu Rev Pathol (2009) 4.92
Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene (2006) 4.62
Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene (2006) 4.53
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A (1996) 4.49
Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA (2002) 4.32
Mesothelin: a new target for immunotherapy. Clin Cancer Res (2004) 4.30
Digital karyotyping. Proc Natl Acad Sci U S A (2002) 3.96
The cell of origin of ovarian epithelial tumours. Lancet Oncol (2008) 3.74
Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A (1994) 3.50
Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer (2009) 3.46
Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med (2004) 3.39
Fatty acid synthase and cancer: new application of an old pathway. Cancer Res (2006) 3.37
Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res (2000) 3.37
The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol (2000) 3.34
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem (2003) 3.30
Nucleus accumbens neurons are innately tuned for rewarding and aversive taste stimuli, encode their predictors, and are linked to motor output. Neuron (2005) 3.30
Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science (1995) 3.10
Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res (2007) 3.07
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res (2005) 2.92
Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res (2004) 2.66
Notch3 gene amplification in ovarian cancer. Cancer Res (2006) 2.66
Gene expression patterns in ovarian carcinomas. Mol Biol Cell (2003) 2.55
Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol (2003) 2.51
The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev (2001) 2.47
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer (2004) 2.38
Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol (2005) 2.34
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A (2005) 2.29
Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res (1996) 2.18
Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene (2003) 2.16
Purification and characterization of a human factor that assembles and remodels chromatin. J Biol Chem (2000) 2.13
Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res (2005) 2.07
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res (2005) 2.05
Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res (2003) 2.01
Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol (2008) 2.01
Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol (1997) 1.93
Coordinately up-regulated genes in ovarian cancer. Cancer Res (2001) 1.93
Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer (1996) 1.92
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. Am J Obstet Gynecol (2007) 1.80
Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol (2004) 1.79
Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A (2004) 1.77
Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol (1997) 1.76
Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. J Clin Invest (1995) 1.72
Drug addiction: the yin and yang of hedonic homeostasis. Neuron (1996) 1.72
Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res (1997) 1.70
Amplicon profiles in ovarian serous carcinomas. Int J Cancer (2007) 1.70
Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol (1996) 1.68
Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res (2006) 1.62
Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res (2007) 1.61
Functional analysis of the subunits of the chromatin assembly factor RSF. Mol Cell Biol (2003) 1.56
OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology (1995) 1.56
Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene (2009) 1.54
A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci U S A (2006) 1.52
Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res (2007) 1.51
A role for the yeast SWI/SNF complex in DNA replication. Nucleic Acids Res (1999) 1.51
Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem (2004) 1.50
Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene (2005) 1.48
Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol (2003) 1.37
Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics (2008) 1.32
Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics (2005) 1.30
Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res (2005) 1.28
Cloning and mapping of SMARCA5 encoding hSNF2H, a novel human homologue of Drosophila ISWI. Cytogenet Cell Genet (1998) 1.28
MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells. Br J Cancer (2008) 1.25
Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Commun (2009) 1.25
BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res (2005) 1.24
NAC-1 is a brain POZ/BTB protein that can prevent cocaine-induced sensitization in the rat. J Neurosci (2000) 1.23
A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion. J Biol Chem (2001) 1.23
Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res (2005) 1.22
Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biol (2004) 1.21
Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res (2003) 1.20
Apolipoprotein E secretion by macrophages: its potential physiological functions. Curr Opin Lipidol (1996) 1.20
Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Clin Biochem (2000) 1.20
Receptors of the low density lipoprotein (LDL) receptor family in man. Multiple functions of the large family members via interaction with complex ligands. Biol Chem (1998) 1.20
The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms. Cancer Res (2009) 1.20
Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res (2009) 1.20
Hepatitis B virus pX interacts with HBXAP, a PHD finger protein to coactivate transcription. J Biol Chem (2002) 1.19
NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway. Oncogene (2009) 1.18
Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem (2005) 1.18
Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours. Histopathology (2009) 1.17
NAC-1 controls cell growth and survival by repressing transcription of Gadd45GIP1, a candidate tumor suppressor. Cancer Res (2007) 1.16
The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer. J Pathol (1995) 1.16
The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res (2003) 1.15
BEN: a novel domain in chromatin factors and DNA viral proteins. Bioinformatics (2008) 1.14
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res (2006) 1.14
MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells. Cancer Res (2008) 1.13
HBXAP, a novel PHD-finger protein, possesses transcription repression activity. Genomics (2002) 1.13
Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood (2006) 1.13
HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res (2003) 1.13
Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin Chem (2008) 1.11
Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation. J Cell Mol Med (2009) 1.11
Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Hum Pathol (2008) 1.11
Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer (2005) 3.26
Notch3 gene amplification in ovarian cancer. Cancer Res (2006) 2.66
MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One (2008) 2.60
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A (2005) 2.29
Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res (2008) 2.26
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res (2004) 1.89
A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci U S A (2006) 1.52
Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch (2006) 1.49
Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res (2010) 1.48
Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol (2010) 1.45
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med (2013) 1.38
Fine-needle aspiration cytology vs. core biopsy in the diagnosis of breast lesions. Diagn Cytopathol (2003) 1.36
Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer (2010) 1.35
Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Ther (2006) 1.32
Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor. Cancer Res (2004) 1.28
Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res (2005) 1.22
Laminin-induced signaling in tumor cells. Cancer Lett (2005) 1.21
miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med (2011) 1.21
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol (2006) 1.21
Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. Am J Obstet Gynecol (2010) 1.20
Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am J Clin Pathol (2005) 1.16
Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Hum Pathol (2008) 1.11
Retracted Risk markers of oral cancer in clinically normal mucosa as an aid in smoking cessation counseling. J Clin Oncol (2005) 1.09
Fusion of the ZC3H7B and BCOR genes in endometrial stromal sarcomas carrying an X;22-translocation. Genes Chromosomes Cancer (2013) 1.07
Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol (2010) 1.07
Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas. J Oncol (2010) 1.07
Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS One (2010) 1.06
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm (2011) 1.06
Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions. Clin Exp Metastasis (2010) 1.04
Do random estimations of vitamin D3 and parathyroid hormone reflect the 24-h profile in the critically ill? Intensive Care Med (2011) 1.02
Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma. Hum Pathol (2009) 1.00
Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression. Lung Cancer (2006) 0.99
Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma. Hum Pathol (2012) 0.99
IKK-ε coordinates invasion and metastasis of ovarian cancer. Cancer Res (2012) 0.99
Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer (2014) 0.99
The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells. BMC Cancer (2008) 0.98
Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer (2007) 0.98
Genomic aberration patterns and expression profiles of squamous cell carcinomas of the vulva. Genes Chromosomes Cancer (2013) 0.96
Genomic aberrations in borderline ovarian tumors. J Transl Med (2010) 0.95
Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. Hum Pathol (2009) 0.95
Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer (2008) 0.95
The diagnostic role of claudins in serous effusions. Am J Clin Pathol (2007) 0.95
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res (2012) 0.94
BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer. Clin Cancer Res (2007) 0.94
Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma. Int J Cancer (2010) 0.93
S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep (2012) 0.93
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum Pathol (2011) 0.92
Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch (2006) 0.92
Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma. Int J Surg Pathol (2002) 0.92
Expression and clinical role of protein of regenerating liver (PRL) phosphatases in ovarian carcinoma. Int J Mol Sci (2011) 0.91
The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecol Oncol (2004) 0.91
Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival. Hum Pathol (2011) 0.91
Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch (2014) 0.90
Large scale genomic instability as an additive prognostic marker in early prostate cancer. Cell Oncol (2009) 0.90
Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. Hum Pathol (2013) 0.90
Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. Hum Pathol (2007) 0.90
Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells. Cancer Res (2008) 0.89
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Mol Cancer (2005) 0.89
Cystic change in metastatic lymph nodes: a common diagnostic pitfall in fine-needle aspiration cytology. Diagn Cytopathol (2002) 0.89
Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. Gynecol Oncol (2004) 0.89
Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer (2005) 0.89
Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. Hum Pathol (2010) 0.88
Novel fusion of MYST/Esa1-associated factor 6 and PHF1 in endometrial stromal sarcoma. PLoS One (2012) 0.88
Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions. Clin Cancer Res (2007) 0.87
Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions. Hum Pathol (2009) 0.87
Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications. Virchows Arch (2009) 0.87
Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma. Mod Pathol (2006) 0.87
Tenascin-X is a novel diagnostic marker of malignant mesothelioma. Am J Surg Pathol (2009) 0.87
RNA sequencing identifies fusion of the EWSR1 and YY1 genes in mesothelioma with t(14;22)(q32;q12). Genes Chromosomes Cancer (2013) 0.87
Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites. Tumour Biol (2009) 0.86
Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions. Hum Pathol (2011) 0.86
Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol (2003) 0.86
Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters. Am J Clin Pathol (2009) 0.86
Angiogenic molecule expression is downregulated in effusions from breast cancer patients. Breast Cancer Res Treat (2005) 0.86
Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status. Tumour Biol (2011) 0.86
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases. Virchows Arch (2012) 0.86
Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am J Surg Pathol (2013) 0.85
The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma. Gynecol Oncol (2006) 0.85
D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol (2006) 0.85
Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature. Curr Opin Oncol (2004) 0.85
Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary. Am J Obstet Gynecol (2008) 0.85
The anti-apoptotic activity of BAG3 is restricted by caspases and the proteasome. PLoS One (2009) 0.85
Borderline ovarian tumours. Best Pract Res Clin Obstet Gynaecol (2012) 0.84
Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions. Int J Gynecol Cancer (2010) 0.84
Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome. Cancer (2011) 0.84
Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors. Diagn Cytopathol (2010) 0.84
Retracted Molecular based treatment of oral cancer. Oral Oncol (2003) 0.84
Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities. Virchows Arch (2008) 0.84
Breast carcinoma cells in primary tumors and effusions have different gene array profiles. J Oncol (2009) 0.83
The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma. Hum Pathol (2006) 0.83
Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma. Int J Gynecol Pathol (2009) 0.83
Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions. Am J Clin Pathol (2007) 0.83
Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models. Hum Pathol (2010) 0.83
Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome. Am J Clin Pathol (2004) 0.82
Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions. Acta Cytol (2006) 0.82
Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells. Gynecol Oncol (2011) 0.82
Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV? Eur J Cancer (2012) 0.82
Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary. Am J Obstet Gynecol (2008) 0.81